Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Luigia Carbone

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Frontiers in Oncology|August 16, 2024
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patientsFrancesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, et al.
Frontiers in Oncology|April 29, 2026
Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?Francesca Romana Di Pietro, Rosa Falcone, Sofia Verkhovskaia, et al.
Current Oncology (Toronto, Ont.)|January 26, 2024
Primary Mucosal Melanoma: Clinical Experience from a Single Italian CenterRosa Falcone, Sofia Verkhovskaia, Francesca Romana Di Pietro, et al.
BMC Cancer|October 1, 2024
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experienceFrancesca Romana Di Pietro, Daniele Marinelli, Sofia Verkhovskaia, et al.
Cancers|October 16, 2024
Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World StudySofia Verkhovskaia, Rosa Falcone, Francesca Romana Di Pietro, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Frontiers in Oncology|August 16, 2024
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patientsFrancesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, et al.
Frontiers in Oncology|April 29, 2026
Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?Francesca Romana Di Pietro, Rosa Falcone, Sofia Verkhovskaia, et al.
Current Oncology (Toronto, Ont.)|January 26, 2024
Primary Mucosal Melanoma: Clinical Experience from a Single Italian CenterRosa Falcone, Sofia Verkhovskaia, Francesca Romana Di Pietro, et al.
BMC Cancer|October 1, 2024
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experienceFrancesca Romana Di Pietro, Daniele Marinelli, Sofia Verkhovskaia, et al.
Cancers|October 16, 2024
Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World StudySofia Verkhovskaia, Rosa Falcone, Francesca Romana Di Pietro, et al.
Pageof 3